Janssen faces fresh claim over cancer drug royalties
A Danish biotech company has renewed its dispute with Belgium’s Janssen Pharmaceuticals, claiming US$405 million over a blood cancer treatment just weeks after a tribunal dismissed an earlier arbitration concerning the same licensing agreement.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.